Infection-related adverse events comparison of bortezomib, carfilzomib and ixazomib: a pharmacovigilance study based on FAERS
In real-world pharmacovigilance studies, PIs are associated with infection-related adverse events, which is crucial for the safe use of PIs in the treatment of MM. However, further research is needed to validate the hypotheses generated in this study.
Authors
- Chenhuan Xiang (ORCID: https://orcid.org/0000-0003-3971-1099)
- Juanjuan Ti
- Tao Wang (ORCID: https://orcid.org/0000-0002-5728-6463)
- Shaoli Zhang (ORCID: https://orcid.org/0009-0004-1836-714X)
- Rongrong Guo (ORCID: https://orcid.org/0000-0002-2861-3023)
Institutions
- Shanxi Medical University (CN)
- Shanxi Academy of Medical Sciences (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1080/14740338.2025.2494692
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00